PsychiatryNews.net

Psychiatry Xagena

Since the 1970s, clinicians have increasingly become more familiar with hyperprolactinemia ( HPRL ) as a common adverse effect of antipsychotic medication, which remains the cornerstone of pharmacolog ...


Since 1999, there has been a dramatic increase in opioid overdose deaths and addiction to opioid drugs, including both prescription opioid pain relievers and heroin. Increased rates of addiction hav ...


A study has determined, using research on Duloxetine ( Cymbalta ) for major depressive disorder as an example, if there are inconsistencies between protocols, clinical study reports, and main publicly ...


A study has investigated if the widely publicized warnings in 2003 from the FDA ( Food and Drug Administration ) about a possible increased risk of suicidality with antidepressant use in young people ...


In Sweden, a study has investigated the association between drug treatment for attention-deficit / hyperactivity disorder ( ADHD ) and risk of concomitant suicidal behaviour among patients with ADHD. ...


A systematic review and meta-analysis of observational studies has investigated the change in mental health after smoking cessation compared with continuing to smoke. Eligibility criteria were long ...


A systematic review and meta-analysis was performed on published and unpublished efficacy studies of Agomelatine in people with depression. The eligibility criteria were double blind randomised pla ...


Combining pharmacotherapies for tobacco-dependence treatment may increase smoking abstinence. A study has determined efficacy and safety of Varenicline and Bupropion sustained-release ( SR; combinatio ...


A review on the efficacy and the tolerability of Quetiapine ( Seroquel ), either as monotherapy or combination therapy, for acute bipolar depression, was done. Researchers have included all randomi ...


Ketamine's efficacy in depressive disorders has been established in several controlled trials. The aim of a study was to determine whether or not Ketamine administration significantly improves depress ...


The purpose of a study was to determine whether stimulant users are at higher risk of a later cardiovascular event than are non-users, examining this association in both a national cohort and a popula ...


Psychotherapy is the treatment of choice for patients with anorexia nervosa, although evidence of efficacy is weak. The Anorexia Nervosa Treatment of OutPatients ( ANTOP ) study aimed to assess the ef ...


Health anxiety has been treated by therapists expert in cognitive behaviour therapy with some specific benefit in some patients referred to psychological services. Those in hospital care have been les ...


The aim of a study was to determine the prevalence of drug-induced long QT at admission to a public psychiatric hospital and to document the associated factors using a cross-sectional approach. All ...


In 2009, the FDA ( Food and Drug Administration ) issued a black box warning for Varenicline ( Champix; in Europe: Champix ) regarding neuropsychiatric events. Researchers used data from randomized c ...


Anorexia nervosa is characterised by a chronic course that is refractory to treatment in many patients and has one of the highest mortality rates of any psychiatric disorder. Deep brain stimulation ( ...


Delirium is frequently diagnosed in critically ill patients and is associated with poor clinical outcomes. Haloperidol ( Haldol, Serenase ) is the most commonly used drug for delirium despite little e ...


A study has prospectively evaluated consumptions of sweetened beverages, coffee and tea in relation to depression among older US adults. Sweetened beverages, coffee and tea are commonly consumed world ...


Risperidone ( Risperdal ) is an atypical antipsychotic agent indicated for the treatment or management of schizophrenia, inappropriate behaviour associated with severe dementia and manic episodes asso ...


Clinicians have long speculated that poor sleep may be a mechanism involved in the higher risk of further cardiac events or death among those with post-traumatic stress disorder ( PTSD ) following an ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati